Achieve Life Sciences to Present at the MicroCap Rodeo Winter Wonderland Conference on February 16, 2021

Rhea-AI Summary

Achieve Life Sciences (NASDAQ: ACHV) will present at the MicroCap Rodeo Winter Wonderland Conference from February 16-19, 2021. CEO John Bencich is scheduled to speak on February 16 at 12:30 p.m. EST. The presentation will be available for live streaming and replay at their investor relations site.

The conference highlights 35 investment opportunities recommended by institutional investors, focusing on companies like Achieve, which is dedicated to resolving nicotine addiction through its product, cytisinicline.

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will present at the MicroCap Rodeo Winter Wonderland Conference, which is being held virtually on February 16^th - 19^th, 2021.

Mr. John Bencich, Chief Executive Officer of Achieve Life Sciences, is scheduled to present on Tuesday, February 16^th at 12:30 p.m. EST, with one-on-one meetings to be held throughout the conference.

The presentation will be webcast live and available for replay http://ir.achievelifesciences.com/events-and-webcasts. For registration information and meeting requests please visit https://microcaprodeo.com/signup.

About the MicroCap Rodeo Winter Wonderland Conference
The MicroCap Rodeo Winter Wonderland conference is a virtual event showcasing 35 best ideas from the buy side. Qualified institutional investors recommended each of the 35 companies represented.

About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.^1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.²

Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

Investor Relations Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4

Media Contact
Glenn Silver
Glenn.Silver@Finnpartners.com
(646) 871-8485

References
¹ World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.

² U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General, 2014.

SOURCE: Achieve Life Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/629219/Achieve-Life-Sciences-to-Present-at-the-MicroCap-Rodeo-Winter-Wonderland-Conference-on-February-16-2021

FAQ

When is Achieve Life Sciences presenting at the MicroCap Rodeo Winter Wonderland Conference?

Achieve Life Sciences will present on February 16, 2021, at 12:30 p.m. EST.

What is cytisinicline and how does it help with smoking cessation?

Cytisinicline is a plant-based alkaloid that helps combat nicotine addiction by reducing withdrawal symptoms and the satisfaction associated with smoking.

Where can I watch the Achieve Life Sciences presentation?

The presentation will be webcast live and available for replay on their investor relations website.

What is the significance of the MicroCap Rodeo Winter Wonderland Conference?

The conference showcases 35 investment opportunities recommended by qualified institutional investors, highlighting promising companies like Achieve Life Sciences.

How long has cytisinicline been used in Central and Eastern Europe?

Cytisinicline has been an approved, branded product in Central and Eastern Europe for over two decades.